Capri­cor gets up to $735M for Duchenne drug's US rights; PCI Biotech ends bile duct can­cer clin­i­cal tri­al

Capri­cor Ther­a­peu­tics is still chug­ging along.

The San Diego biotech signed a new col­lab­o­ra­tion with Japan­ese phar­ma com­pa­ny Nip­pon Shinyaku, whose US sub­sidiary is NS Phar­ma. Capri­cor earns a $30 mil­lion up­front pay­ment to run its Phase III tri­al for its lead Duchenne cell ther­a­py pro­gram while leav­ing the door open for $705 mil­lion in po­ten­tial mile­stones.

Nip­pon Shinyaku, mean­while, gets US dis­tri­b­u­tion rights and will be in charge of such ef­forts. Capri­cor will run the piv­otal study and han­dle man­u­fac­tur­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER